Opinion · VigiEye View Regulatory

Definitions decide pathways: UK gene therapy rewrite means check your category now

The UK will widen its gene therapy definition to catch synthetic and genome-editing products. Regulatory teams should test their pipelines against the new boundary before the legislation arrives.

VigiEye editorial · Fri 20 Nov 2026

The boundary is moving, not the science

Most regulatory attention goes to decisions: approvals, opinions, guidance. The UK's confirmation this week that it will widen the definition of gene therapy medicinal products deserves more attention than it will probably get, because it changes which rulebook a product sits under.

The records are clear on the essentials. Following a consultation, the government will amend the Human Medicines Regulations 2012 so that more synthetic and gene-editing medicines fall under the advanced therapies framework. The MHRA and Northern Ireland's health department will pursue secondary legislation to do it. Support was strong: 83% of the 48 respondents backed the proposals.

My position is that sponsors of synthetic and genome-editing products should treat this as a live classification risk now, not as a legislative curiosity to revisit once the text is published. Classification is the first decision in a development programme. It sets the expectations for quality, clinical design and post-authorisation obligations. A change to the boundary can reach back into programmes that were scoped under a different assumption.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Sources this column is based on

Opinion: this column argues a position. Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.

More analysis & opinionAll →